Exploring ATTR Phenotypes and Identifying Appropriate Opportunities for Pharmacists to Intervene

Program Description

Transthyretin amyloidosis (ATTR) is a life-threatening, progressive, and underrecognized disease characterized by misfolded transthyretin protein that can present with cardiac, neurologic, or mixed phenotypes. ATTR causes significant multisystem burden, and proper management requires accurately differentiating between the various types. Advances in research have contributed to the development of disease-modifying therapies (DMTs) to manage ATTR; however, more research is needed to recognize safety and efficacy, as long-term therapy with these medications may cause treatment barriers. This program will focus on DMTs and investigational therapies for ATTR-cardiomyopathy and ATTR-polyneuropathy, equipping pharmacists to identify ATTR clinical presentation, optimize treatment regimens, and improve patients' health and quality of life. Practical aspects of patient education, therapy adjustments based on lab values, interpretation of relevant laboratory results, and tailoring treatment to individual patient presentations will also be discussed.

Target audience: Health System Pharmacist

Type of activity: Application
Release date: June 30, 2025
Expiration date: June 30, 2026

Time to complete activity: 1.0 hour

Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify the clinical manifestations of transthyretin amyloidosis (ATTR)
• Explore the treatment recommendations for ATTR
• Explain treatment plan recommendations for patients presenting with ATTR-CM, ATTR-PN, and mixed phenotype ATTR
• Provide opportunities for pharmacists to support multidisciplinary interventions for ATTR patients

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-218-H01-P. The activity is available for CE credit through June 30, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Dejan Landup, PharmD, HF-Cert

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Victoria Chirdo; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms